Allysta Pharmaceutical   Report issue

For profit Phase 2 Phase 3
Founded: Belmont CA United States (2016)

Organization Overview

First Clinical Trial
2018
NCT03452033
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Allysta Pharmaceutical

Active Ingredients

Drugs in Phase 3 Trials (1)

aly688 (3 trials)

Drugs in Phase 2 Trials (1)

h-1337 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Dry Eye Syndromes (Phase 2)

Eye Diseases (Phase 2)

Glaucoma (Phase 2)

Glaucoma, Open-Angle (Phase 2)

Keratoconjunctivitis Sicca (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 4
  • # of Trial APIs: 2